InMed Pharmaceuticals is pleased to welcome the BayMedica team following the acquisition in October 2021.
Meet Chris Meiering, our VP of Commercial Operations. Chris talks about the unique start to his career in pet nutrition and how he got into the business of developing rare cannabinoids for the health and wellness sector.
Chris earned his PhD in microbiology, specializing in molecular virology, from the University of Washington and performed his post doctoral research at Stanford University.
Dr. Shane Johnson, GM of BayMedica, InMed’s subsidiary, answers these questions: What is the minimum GMP standard that consumers should expect? What quality controls should
Dr. Shane Johnson, GM of BayMedica, InMed’s subsidiary, answers these questions: What is the role of the endocannabinoid system? How do cannabinoids interact with the
Dr. Shane Johnson, GM of BayMedica, InMed’s subsidiary, answers these questions: What are illegal synthetic cannabinoids? How are illegal synthetic cannabinoids different from bioidentical synthesized
© Copyright 2023 InMed Pharmaceuticals Inc.
"*" indicates required fields